X

Trial Profile

An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms CheckMate870
Sponsors Bristol-Myers Squibb

Most Recent Events

24 Sep 2021 Status changed from active, no longer recruiting to completed.
24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II
22 Aug 2019 Planned End Date changed from 29 Jul 2022 to 29 Jul 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com